DGAP-Adhoc

aap Implantate AG: Resolution on a Capital Reduction

DGAP-Ad-hoc: aap Implantate AG / Key word(s): Corporate Action/Miscellaneous aap Implantate AG: Resolution on a Capital Reduction 19-Jul-2017 / 10:23 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The Management Board of aap Implantate AG resolved on 19 July 2017 with the approval of the Supervisory Board of the same day to redeem the 2,249,746 no-par value shares bought by means of the voluntary public share buyback offer of aap Implantate AG and to reduce the company's share capital by the corresponding amount of EUR 2,249,746.00. The redemption and capital reduction take place without a further resolution of the Annual General Meeting by exercising the authorization of the Annual General Meeting of 13 June 2014. After the implementation of the capital reduction aap Implantate AG's share capital amounts to EUR 28,582,410.00 and is divided into 28,582,410 no-par value ordinary bearer shares in a proportional amount of EUR 1.00 per no-par value share of the share capital.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.